December 28, 2018 08:18 AM ESTUpdated 08:51 AM

Backed by a pioneer in BiTE tech, Harpoon marks a course for an IPO and an early display of potential

John Carroll

Editor & Founder

Can a next-gen BiTE devised by a pioneer in the field attract investors into an oncology IPO based almost entirely on mouse data? Harpoon Therapeutics …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Backed by a pioneer in BiTE tech, Harpoon marks a course for an IPO and an early display of potential

John Carroll

Editor & Founder

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Backed by a pi­o­neer in BiTE tech, Har­poon marks a course for an IPO and an ear­ly dis­play of po­ten­tial

Editor & Founder

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Backed by a pioneer in BiTE tech, Harpoon marks a course for an IPO and an early display of potential